
|Articles|April 26, 2004
Proprietary sustained-release dexamethasone implant shows promise for treating persistent cystoid macular edema
Results of a controlled Phase I/II study show that the bioerodable, sustained-release,dexamethasone implant (Posurdex, Allergan) results in a statistically significantincrease in ETDRS standardized visual acuity in eyes with persistent cystoidmacular edema (CME), said Mark S. Blumenkranz, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
2
Beyond the surface: Tackling complex dry eye cases
3
An Extreme Case of Demodex Blepharitis: From Misdiagnosis to Remarkable Recovery
4
Redefining glaucoma care: Where innovation meets clinical insight
5



















































.png)


